Sponsor
|
Studies ↑
|
Description
|
Ready to Share
|
Created
|
|
ASTELLAS-015K-CL-PS01
|
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis
|
3/31/2020
|
|
ASTELLAS-015K-CL-RA21
|
A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients who have had an Inadequate Response to Methotrexate
|
2/18/2020
|
|
ASTELLAS-015K-CL-RA22
|
A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients
|
2/18/2020
|
|
ASTELLAS-015K-CL-RA25
|
A Phase 2 Open-label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
2/18/2020
|
|
ASTELLAS-015K-CL-RAJ1
|
Phase 2b Study of ASP015K – A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients –
|
7/14/2020
|
|
ASTELLAS-015K-CL-RAJ3
|
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs -
|
7/14/2020
|
|
ASTELLAS-015K-CL-RAJ4
|
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX -
|
7/14/2020
|
|
ASTELLAS-0456-CL-1021
|
Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)
|
2/28/2020
|
|
ASTELLAS-0456-CL-1031
|
Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients with Chronic Constipation (Not Including Constipation Due to Organic Diseases) -
|
2/28/2020
|
|
ASTELLAS-1707-CL-0011
|
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment
|
2/18/2020
|